Skyhawk Therapeutics Announces First U.S. Patients Dosed in Pivotal FALCON-HD Study Evaluating SKY-0515 in Huntington's Disease

The Quick Take
More than 50,000 doses of SKY-0515 have now been administered to patients. BOSTON, Nov. 5, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate RNA targets, today announced that the first U.S....
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
In HelloNation, HVAC Expert Sean McGorry Highlights Water Quality in New Hampshire Homes
The article outlines practical steps to maintain safe water, improve filtration performance, and support long-term system reliability. BEDFORD, N.H., Nov. 5,…
Business
New Report: Tort Lawsuit Costs Hit More Than $4,900 Per American Household
U.S. tort litigation system costs reached nearly $656 billion in 2025, growing faster than the economy and adding to affordability pressures on families…
Business
KLA Declares Regular Cash Dividend
MILPITAS, Calif., Nov. 5, 2026 /PRNewswire/ -- The KLA Corporation (NASDAQ: KLAC) Board of Directors today declared a quarterly cash dividend of $0.23 per…
Business
Cheche Group Announces Extraordinary General Meeting
BEIJING, Nov. 5, 2026 /PRNewswire/ -- Cheche Group Inc. (NASDAQ: CCG) ("Cheche" or the "Company"), China's leading auto insurance technology platform, today…
